Completed

Alpha Interferon and Zidovudine for HIV-1 Related Progressive Multifocal Leukoencephalopathy

What is being tested

Interferon alfa-2b

+ Zidovudine

Drug

Who is being recruted

Infectious Encephalitis+27

+ Blood-Borne Infections

+ Neuroinflammatory Diseases

From 18 to 65 Years

+5 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Interventional

See protocol details

Summary

Principal SponsorUniversity of Miami

Last updated: June 24, 2005

Sourced from a government-validated database.Claim as a partner

This study focuses on understanding the effectiveness of two medications, alpha interferon (IFN-A2b) and zidovudine (AZT), in treating a condition called progressive multifocal leukoencephalopathy (PML). PML is a complication that can arise in individuals living with HIV-1 infection. The goal is to find a potential treatment that could help improve the care for those affected by this condition. Participants in this study will receive both alpha interferon (IFN-A2b) and zidovudine (AZT) as part of their treatment. The effectiveness of these medications will be evaluated by observing changes in the participants' health over time. It's important to note that the specific outcomes being measured are not provided in the study details.

NCT00002270

Principal SponsorUniversity of Miami

Last updated: June 24, 2005

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Infectious EncephalitisBlood-Borne InfectionsNeuroinflammatory DiseasesUrogenital DiseasesGenital DiseasesBrain DiseasesCentral Nervous System DiseasesCentral Nervous System InfectionsCommunicable DiseasesDemyelinating DiseasesDNA Virus InfectionsEncephalitisImmunologic Deficiency SyndromesImmune System DiseasesInfectionsNervous System DiseasesRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsEncephalitis, ViralCentral Nervous System Viral DiseasesPolyomavirus InfectionsLeukoencephalopathiesAcquired Immunodeficiency SyndromeLeukoencephalopathy, Progressive MultifocalHIV Infections

Criteria

2 inclusion criteria required to participate

Biopsy proven progressive multifocal leukoencephalopathy (PML).

HIV seropositivity by both ELISA and Western blot.

3 exclusion criteria prevent from participating

Prior or concomitant central nervous system disease (CNS) such as toxoplasmosis, multiple sclerosis (MS), or neurosyphilis.

Patients receiving interferon for other reasons.

Intolerant to interferon.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Univ of Miami School of Medicine

Miami, United StatesOpen Univ of Miami School of Medicine in Google Maps

CompletedOne Study Center